Sugi Predict

Sugi Predict / Compounds / SCHEMBL2707159

SCHEMBL2707159

SCHEMBL2707159

CC(C)(C)OC(=O)N1CCC(=O)C(OCc2ccccc2)C1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ DDB1 Q16531 1/20 0.49
▸ CRBN Q96SW2 1/20 0.49
▸ JAK2 O60674 1/20 0.47
▸ JAK1 P23458 1/20 0.47
▸ STS P08842 1/20 0.47
▸ GPR119 Q8TDV5 2/20 0.45
▸ PARP1 P09874 1/20 0.44
▸ USP30 Q70CQ3 2/20 0.43
▸ KLK7 P49862 1/20 0.43
▸ PDK4 Q16654 1/20 0.43
▸ KDM4E B2RXH2 1/20 0.42
▸ PKM P14618 1/20 0.42
▸ PRMT5 O14744 2/20 0.41
▸ WDR77 Q9BQA1 2/20 0.41
▸ ESR2 Q92731 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ THRB P10828 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ YAP1 P46937 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15720471 0.88 STS (0.47) DDB1CRBNJAK2JAK1STS
SCHEMBL9721933 0.86 TSHR (0.48) GAASMN1; SMN2
SCHEMBL964263 0.85 SMN1; SMN2 (0.53) GAASMN1; SMN2
SCHEMBL2704313 0.84 SMN1; SMN2 (0.41) PKMSMN1; SMN2
SCHEMBL2826934 0.81 NR1H2 (0.40) DDB1CRBNGPR119PDK4KDM4E
SCHEMBL4480437 0.81 JAK2 (0.49) JAK2JAK1STSGPR119PARP1
SCHEMBL942191 0.80 JAK2 (0.55) JAK2JAK1STSGPR119USP30
SCHEMBL20503925 0.80 JAK2 (0.55) JAK2JAK1STSGPR119USP30
SCHEMBL697850 0.80 JAK2 (0.55) JAK2JAK1STSGPR119USP30
SCHEMBL15293404 0.79 CTSK (0.49) JAK2JAK1STSGPR119PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12441704-B2 Compounds active towards nuclear receptors NUEVOLUTION A/S (DK) 2025-10-14 — — US disclosed
CN-114728170-B Compounds active on nuclear receptors 纽韦卢森公司 2024-03-01 — — CN disclosed
US-11780843-B2 Compounds active towards nuclear receptors NUEVOLUTION A/S (DK) 2023-10-10 — — US disclosed
US-20230271937-A1 COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS NUEVOLUTION A/S (DK) 2023-08-31 — — US disclosed
US-20230271937-A1 COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS NUEVOLUTION A/S (DK) 2023-08-31 — — US disclosed
US-20230271937-A1 COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS NUEVOLUTION A/S (DK) 2023-08-31 — — US disclosed
US-11685727-B2 Compounds active towards nuclear receptors NUEVOLUTION A/S (DK) 2023-06-27 — — US disclosed
US-11685727-B2 Compounds active towards nuclear receptors NUEVOLUTION A/S (DK) 2023-06-27 — — US disclosed
US-11685727-B2 Compounds active towards nuclear receptors NUEVOLUTION A/S (DK) 2023-06-27 — — US disclosed
US-11613532-B2 Compounds active towards nuclear receptors NUEVOLUTION A/S (DK) 2023-03-28 — — US disclosed
US-20170369450-A1 ANTIBACTERIAL COMPOUNDS HAVING BROAD SPECTRUM OF ACTIVITY AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) 2017-12-28 — — US disclosed
US-20170369450-A1 ANTIBACTERIAL COMPOUNDS HAVING BROAD SPECTRUM OF ACTIVITY AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) 2017-12-28 — — US disclosed
WO-2016096686-A1 ANTIBACTERIAL COMPOUNDS HAVING BROAD SPECTRUM OF ACTIVITY AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) 2016-06-23 — — WO disclosed
EP-2226322-B1 IMIDAZOLE CARBONYL COMPOUND DAIICHI SANKYO CO LTD (JP) 2015-01-21 — — EP disclosed
US-8927588-B2 Imidazole carbonyl compound DAIICHI SANKYO COMPANY, LIMITED (JP) 2015-01-06 — — US disclosed
US-20140073622-A1 IMIDAZOLE CARBONYL COMPOUND DAIICHI SANKYO COMPANY, LIMITED (JP) 2014-03-13 — — US disclosed
US-8536197-B2 Imidazole carbonyl compound DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-09-17 — — US disclosed
WO-2012025811-A1 INDOLYLPYRIMIDINES AS MODULATORS OF GPR119 LUPIN LIMITED (IN) 2012-03-01 — — WO disclosed
US-20100311966-A1 IMIDAZOLE CARBONYL COMPOUND DAIICHI SANKYO COMPANY, LIMITED (JP) 2010-12-09 — — US disclosed
EP-2226322-A1 IMIDAZOLE CARBONYL COMPOUND Daiichi Sankyo Company, Limited (JP) 2010-09-08 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11780843-B2 Compounds active towards nuclear receptors NCOA1, NR1H2, NCOA3 DDB1 1190/4885CRBN 2170/4885JAK2 3057/4885
US-11685727-B2 Compounds active towards nuclear receptors NCOA1, NR1H2, NCOA3 DDB1 1190/4885CRBN 2170/4885JAK2 3057/4885
US-20170369450-A1 ANTIBACTERIAL COMPOUNDS HAVING BROAD SPECTRUM OF ACTIVITY MRPL21, ABCG2, CLPP DDB1 1785/4885CRBN 4499/4885JAK2 4263/4885
US-11613532-B2 Compounds active towards nuclear receptors NCOA1, NR1H2, NCOA3 DDB1 1190/4885CRBN 2170/4885JAK2 3057/4885
US-20230271937-A1 COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS NCOA1, NR1H2, NCOA3 DDB1 1190/4885CRBN 2170/4885JAK2 3057/4885
US-20100311966-A1 IMIDAZOLE CARBONYL COMPOUND TOP1, TOP2B, TOP2A DDB1 29/4885CRBN 3329/4885JAK2 3941/4885
US-12441704-B2 Compounds active towards nuclear receptors NCOA1, NR1H2, NCOA3 DDB1 1190/4885CRBN 2170/4885JAK2 3057/4885
US-20140073622-A1 IMIDAZOLE CARBONYL COMPOUND TOP1, TOP2B, TOP2A DDB1 32/4885CRBN 3578/4885JAK2 3424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.